Enhancing the antitumoral effect of hypericin‐mediated photodynamic therapy by hyperthermia

In the previous study, we have found a synergistic effect on the RIF‐1 tumor cell killing when hypericin‐mediated photodynamic therapy (PDT) was combined with hyperthermia. The purpose of the present study was to investigate the antitumoral effect of hypericin‐PDT in combination with hyperthermia in the RIF‐1 mouse tumor model.

[1]  R. Pedley,et al.  Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. , 2001, Cancer research.

[2]  M W Berns,et al.  Demonstration of synergistic effects of hyperthermia and photodynamic therapy using the chick chorioallantoic membrane model , 1992, Lasers in surgery and medicine.

[3]  K. Sano,et al.  The anti-tumor effect of photodynamic therapy evaluated by bromodeoxyuridine immunohistochemistry. , 1998, International journal of oral and maxillofacial surgery.

[4]  K Svanberg,et al.  Tumour vessel damage resulting from laser-induced hyperthermia alone and in combination with photodynamic therapy. , 1997, Cancer letters.

[5]  W. Merlevede,et al.  Cytotoxicity and Antiproliferative Effect of Hypericin and Derivatives after Photosensitization , 1998, Photochemistry and photobiology.

[6]  T. Roskams,et al.  Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF‐1 mouse tumor model , 2002, International journal of cancer.

[7]  J. Gray,et al.  A new mouse tumor model system (RIF-1) for comparison of end-point studies. , 1980, Journal of the National Cancer Institute.

[8]  P. D. de Witte,et al.  Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy. , 2001, International journal of oncology.

[9]  W. Wilson,et al.  Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. , 2000, Cancer research.

[10]  J. Uitto,et al.  Hyperthermia potentiates the effects of aluminum phthalocyanine tetrasulfonate‐mediated photodynamic toxicity in human malignant and normal cell lines , 1991, Lasers in surgery and medicine.

[11]  B W Henderson,et al.  Interaction of photodynamic therapy and hyperthermia: tumor response and cell survival studies after treatment of mice in vivo. , 1985, Cancer research.

[12]  Yan Xu,et al.  Efficacy of antitumoral photodynamic therapy with hypericin: Relationship between biodistribution and photodynamic effects in the RIF‐1 mouse tumor model , 2001, International journal of cancer.

[13]  C. M. Allen,et al.  Photodynamic therapeutics: basic principles and clinical applications. , 1999, Drug discovery today.

[14]  D. Meruelo,et al.  The chemical and biological properties of hypericin—a compound with a broad spectrum of biological activities , 1995, Medicinal research reviews.

[15]  B Chen,et al.  Synergistic effect of photodynamic therapy with hypericin in combination with hyperthermia on loss of clonogenicity of RIF-1 cells. , 2001, International journal of oncology.

[16]  T. Mang,et al.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. , 1985, Cancer research.

[17]  T. Dubbelman,et al.  Potentiation of thermal inactivation of glyceraldehyde-3-phosphate dehydrogenase by photodynamic treatment. A possible model for the synergistic interaction between photodynamic therapy and hyperthermia. , 1991, The Biochemical journal.

[18]  T. Dubbelman,et al.  Synergistic Interaction of Photodynamic Treatment with the Sensitizer Aluminum Phthalocyanine and Hyperthermia on Loss of Clonogenicity of CHO Cells , 1996, Photochemistry and photobiology.

[19]  T J Dougherty,et al.  TIME and SEQUENCE DEPENDENT INFLUENCE OF IN VITRO PHOTODYNAMIC THERAPY (PDT) SURVIVAL BY HYPERTHERMIA , 1985, Photochemistry and photobiology.

[20]  J. J. Schuitmaker,et al.  Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C. , 1995, British Journal of Cancer.